Clinical trials: Venous Thromboembolic Disease
Traumatic Injury, Venous Thromboembolism
Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients
This is a pilot study to determine if anti-thrombin III (AT-III) serum concentrations differ between patients with normal versus subtherapeutic anti-Xa trough concentrations when placed on enoxaparin 30 mg twice daily for VTE…
- Trial name
- NCT02412982
- Testing
- Enoxaparin 40 mg q12h, Enoxaparin 30 mg q8h
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- University of Cincinnati
Recurrent Venous Thrombosis
Risk of Recurrent Venous Thromboembolism After Provoked Venous Thromboembolism
Venous thromboembolism (VTE) is a common disease with an incidence of 1-2/1000 persons per year. VTE is a chronic disease with a considerable risk of recurrence. Patients with unprovoked VTE, i.e.
- Trial name
- AURECpro (NCT04124159)
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Medical University of Vienna
Venous Thromboembolic Disease, Kidney Failure, Chronic
Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data
Patients with end stage renal disease (ESRD) are at significantly increased risk of thrombosis and bleeding relative to those with normal renal function which makes anticoagulation particularly challenging.
- Trial name
- NCT04818151
- Testing
- Warfarin, Apixaban
- Where
- United States
- Volunteers
- 14,914 people
- Sponsor
- Johns Hopkins University
Covid19, Thrombosis Embolism
COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications
Novel coronavirus 2019 (COVID-19) has emerged as a major international public health concern. While much of the morbidity and mortality associated with COVID-19 has been attributed to acute respiratory distress syndrome (ARDS) or…
- Conditions
- Covid19, Thrombosis Embolism, DVT, Pulmonary Embolism
- Trial name
- CORONA-VTE NET (NCT04535128)
- Testing
- No intervention
- Where
- United States
- Volunteers
- 11,000 people
- Sponsor
- Brigham and Women's Hospital
Venous Thromboembolism
An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism
This is an observational study in which only data will be collected from children with venous thromboembolism who are prescribed rivaroxaban or warfarin by their doctors.
- Trial name
- NCT06278051
- Testing
- Rivaroxaban granules for oral suspension, Warfarin
- Where
- 2 sites in Japan
- Volunteers
- 320 people
- Sponsor
- Bayer
Advanced Gastric Cancer
Venous Thromboembolism in Advanced Gastric Cancer Patients
Venous thromboembolism (VTE), which includes pulmonary embolism (PE) and deep vein thrombosis (DVT), is a common complication and leading cause of death in cancer patients.
- Trial name
- NCT01047618
- Where
- South Korea
- Volunteers
- 259 people
- Sponsor
- Asan Medical Center
Pulmonary Embolism, Acute Pulmonary Embolism
CLEANer Aspiration for Pulmonary Embolism
To evaluate the safety and efficacy of the Cleaner™ Pro Thrombectomy System for aspiration thrombectomy in patients with acute pulmonary embolism (PE).
- Conditions
- Pulmonary Embolism, Acute Pulmonary Embolism, Cardiovascular Diseases, Venous Thromboembolism
- Trial name
- CLEAN-PE (NCT06189313)
- Testing
- Cleaner Pro Thrombectomy System
- Where
- 14 sites in United States
- Volunteers
- 125 people
- Sponsor
- Argon Medical Devices
Interstitial Lung Disease, Venous Thromboembolism
Risk Factors of Venous Thrombotic Event in Interstitial Lung Disease
This study aims to determine the incidence of venous thromboembolic events (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), among hospitalized patients with interstitial lung disease (ILD).
- Conditions
- Interstitial Lung Disease, Venous Thromboembolism, Pulmonary Embolism, Deep Venous Thrombosis
- Trial name
- NCT07833254
- Volunteers
- 100 people
- Sponsor
- Sohag University
Sickle Cell Disease, Venous Thrombosis
Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait
Background: Venous thromboembolism (VTE) includes the abnormal clotting of blood in a deep vein of the upper or lower limbs (deep vein thrombosis) that may travel to and block a blood vessel in the lung (pulmonary embolism).
- Conditions
- Sickle Cell Disease, Venous Thrombosis, Sickle Cell Trait, Hypercoagulable State
- Trial name
- NCT04349189
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Embolism, Venous Thromboembolism
Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients
There's no unified recommendation in clinical practice regarding adjusting dosages for different patient types, especially when adverse events occur.
- Conditions
- Pulmonary Embolism, Venous Thromboembolism, Anticoagulant-induced Bleeding
- Trial name
- NCT06194617
- Testing
- Direct oral anticoagulant
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Thromboembolism
Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events
This study is being carried out to study the efficacy and safety of treatment with melagatran injection followed by ximelagatran tablets in preventing blood clots, compared with enoxaparin for a period of 5-6 weeks.
- Trial name
- EXTEND (NCT00206089)
- Testing
- EXANTA
- Where
- 125 sites in Austria, Belgium and 14 more
- Volunteers
- 3,300 people
- Sponsor
- AstraZeneca
Vascular Diseases, Embolism and Thrombosis
Epidemiology of Thromboembolism Disease: A Cohort Study
The purpose of this study is to determine different risk factors of thromboembolic disease. Different points will be studied 1. do different types of thromboembolic disease (distal Deep Vein Thrombosis (DVT), proximal DVT…
- Conditions
- Vascular Diseases, Embolism and Thrombosis, Phlebitis, Venous Insufficiency
- Trial name
- OPTIMEV (NCT00670540)
- Testing
- procedure of Deep Vein Thrombosis (DVT) and PE (Pulmonary Embolism) diagnosis
- Where
- 231 sites in Belgium, France and 1 more
- Volunteers
- 8,256 people
- Sponsor
- University Hospital, Grenoble
Venous Thromboembolism, Venous Thrombosis
Mexican Multidisciplinary Registry of Patients With Venous Thromboembolic Disease
REMMITE, a retrospective and prospective registry with one-year follow-up, will provide valuable insights into the clinical diagnosis, management, treatment trends as well as related outcomes of three cohorts: DVT, DVT-PE, PE…
- Conditions
- Venous Thromboembolism, Venous Thrombosis, Pulmonary Embolism
- Trial name
- REMMITE (NCT02877251)
- Volunteers
- 500 people
- Sponsor
- Registro Mexicano Multidisciplinario De Pacientes Con Enfermedad Tromboembolica Venosa
Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to…
- Conditions
- Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis, Deep Vein Thrombosis, Hospitalism
- Trial name
- eVTE (NCT06232551)
- Testing
- EHR (electronic health record) alert, No EHR (electronic health record) alert
- Where
- United States
- Volunteers
- 152,000 people
- Sponsor
- Scott C. Woller, MD
Pulmonary Embolism
Pulmonary Embolism Registry
Acute Pulmonary Embolism (PE) is the most serious clinical presentation of venous thromboembolism (VTE), a leading cause of cardiovascular mortality, exceeded only by stroke and myocardial infarction.
- Trial name
- PER (NCT05391646)
- Volunteers
- 500 people
- Sponsor
- Universidade do Porto
Primary Total Hip and Knee Arthroplasty
Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty
This is a prospective, randomized study from pre-surgery to 6 weeks post-surgery designed to detect changes in coagulability following elective total knee and hip arthroplasty.
- Trial name
- NCT01809054
- Testing
- Arixtra, Pneumatic compression stockings, Aspirin
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- LifeBridge Health
Venous Thromboembolism
Dose Ranging Study in Elective Total Hip Replacement Surgery
The primary objective is to: demonstrate the efficacy of SR123781A in the prevention of venous thromboembolism (VTE) by the demonstration of a dose-response in patients undergoing total hip replacement surgery.
- Trial name
- DRIVE (NCT00338897)
- Testing
- SR123781A
- Where
- 14 sites in Argentina, Bulgaria and 12 more
- Volunteers
- 1,090 people
- Sponsor
- Sanofi
Deep Venous Thromboses, Pulmonary Embolism
ThRombosis ExclUsion STudy
Primary objective: To demonstrate the ability of STA® - Liatest® D-Di XL combined with a clinical PreTest Probability (PTP) to safely exclude pulmonary embolism (PE) and deep venous thrombosis (DVT) as measured by Negative…
- Conditions
- Deep Venous Thromboses, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- TRUST (NCT03477968)
- Testing
- DDimer test
- Where
- 20 sites in United States, Belgium and 3 more
- Volunteers
- 5,935 people
- Sponsor
- Diagnostica Stago
Venous Thromboembolism
Dose-confirmatory Bridging Study in Total Hip Replacement
The objective of this dose-confirmatory bridging study is to investigate the safety and efficacy of rivaroxaban 5 to 10 mg once-daily (od) dosing in the prevention of venous thromboembolism (VTE) in Japanese patients undergoing…
- Trial name
- NCT01205932
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 41 sites in Japan
- Volunteers
- 402 people
- Sponsor
- Bayer
Thromboembolism
Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT
Blood clots contribute to the death of at least 100,000 Americans each year. Because many of these deaths occur suddenly where treatment is impossible, the best treatment is prevention.
- Trial name
- GIFT (NCT01006733)
- Testing
- Pharmacogenetic, Target INR 1.8
- Where
- 6 sites in United States
- Volunteers
- 1,598 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine